---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-243046"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:13:37.300837+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharma reports CRB-701 Phase 1/2 ORR 47.6% HNSCC, 55.6% mUC at ESMO25

## Summary
- 3.6 mg/kg dose: ORR 47.6% in HNSCC (n=21), 37.5% in cervical cancer (n=16), 55.6% in mUC (n=9).
- No grade 4/5 treatment-related AEs; low discontinuation rate (6.0%) and peripheral neuropathy (8.4% Grade 1/2).
- Responses seen regardless of Nectin-4, HPV, or PD-L1 status; median prior therapies = 3.
- Company plans FDA meeting in 2025 and registrational studies by mid-2026.
- Data presented at ESMO25 from 167 patients; 122 evaluable for efficacy.

## SEC filing metadata
- accession: 0001193125-25-243046
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312525243046/0001193125-25-243046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312525243046/crbp-20251018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-243046
- JSON: https://secwatch.observer/filing/0001193125-25-243046.json
- Plain text: https://secwatch.observer/filing/0001193125-25-243046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.